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To the editors: 
Researchers have begun to study the pharmacological properties of medications 
in different ethnic minority groups and national populations. In this context, 
delimitation of the ethnic or national category is essential to ensure sufficient cultural 
and genetic homogeneity to render the study meaningful. In Spain, the “Latino” 
population tends to have its origins in the Andean region of South America. There is 
some evidence that there is genetic variation in isoenzymes   CYP2D6 and CYP1A2 (1)  
in Amerindians which impacts the gene that encodes the serotonin transporter (1, 2), 
which would appear to impact the metabolism of SSRI drugs but much less so dual 
acting drugs such as duloxetine. 
The antidepressant efficacy of duloxetine in the treatment of major depressive 
disorder (MDD), as well as its faster onset of action, has been demonstrated (3-7). 
These results appear to hold in studies comparing different ethnic samples (8, 9). As 
duloxetine has a dual effect on both the serotonin and norepinephrine systems (10), it 
appears to be a viable therapeutic option for treating depressive disorders, effective in 
the management of somatic symptoms, especially pain, more frequently present 
depressed non-Westernized populations (11). The objective of this study is to examine 
the effectiveness of, and tolerability to, duloxetine in Amerindian immigrants and 
Spaniards of Caucasoid origin diagnosed with major depressive disorder. The main 
study hypothesis is that duloxetine will be effective with both Amerindians and 
Spaniards. 
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Methods 
Study setting and participants 
This was a prospective observational cohort study with a sample of 71 patients 
divided into two cohorts: 30 Spaniards and 41 Amerindian immigrants. Amerindian was 
operationalized narrowly to ensure homogeneity, in accordance with FDA guidelines 
(12). Participants were recruited consecutively from the outpatient services of the 
psychiatry department of Vall d’Hebron University Hospital in Barcelona (Spain) 
during the time period from 2007 and 2010. Any adult between the ages of 18 and 64 
who suffered from MDD as confirmed by the MDD module of the Structured Clinical 
Interview for Axis I DSM-IV (SCID I) (13) and a score of 15 or more on the Hamilton 
Depression Scale (HAMD, 14) and a baseline score of the somatic symptoms subscale 
of the Patient Health Questionnaire (PHQ-15 see below, 15) in treatment with 
Duloxetine (Eli Lilly and Co., Indianapolis, IN, USA) for a maximum of two weeks, 
with no remarkable exclusion characteristics, were included in the study. Patients 
undergoing any antidepressant treatment prior to the initiation of the study were 
excluded. Those patients who required concomitant treatment with anxiolytics were 
treated with low doses of lorazepam, diazepam or clonazepam. It is worth noting that at 
the time of the study, duloxetine was newly present in the Spanish market, and as such 
was not widely prescribed. 
Procedures  
Once recruited, patients participated in a 12 week protocol in which the 
treatment with duloxetine was continued with a dose of 30 or 60 mg that could be 
modified according to patients’ response or with the appearance of adverse effects, in 
accordance with clinical indications. Over the course of the subsequent visits depending 
on tolerability and response, the dose could be reduced, maintained or increased up to a 
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maximum of 120 mg. Effectiveness was assessed for both depressive and somatic 
symptoms. The former were assessed by remission, defined as a final score in the 
Hamilton scale equal to or lower than 7, and response, defined as a final score in the 
Hamilton scale equal to or lower than 50% of the baseline score (5). Remission and 
response were analysed using both an intent-to-treat and a per-protocol approach due to 
the high drop-out rate in the Amerindian group. Tolerability was evaluated by the 
presence of at least one or absence of any adverse effects, regardless of severity. 
Informed consent was obtained from the participants as a requisite for inclusion in the 
study.  
Measures. 
Depressive symptomatology was evaluated using the first 17 items of the 
Hamilton Rating Scale for Depression (HAMD, 14). For a more detailed assessment of 
somatic symptoms the somatic symptoms subscale of the PHQ, a continuous measure of 
somatic symptom severity, was used (15). 
Statistical Analysis 
Baseline characteristics, retention and per protocol results were compared 
among groups using bivariate statistics (T and Chi squared tests and Mann-Whitney U 
for non-normal distributions). A logistic regression was carried out with retention as 
dependent variable and study group as independent variable controlling for 
sociodemographic and clinical characteristics. Last observation carried forward (LOCF) 
was used in order to analyze the effectiveness of duloxetine using an Intent to treat 
(ITT) approach only within patients attending at least a second visit. In addition to 
analysis of response and remission, ITT analyses were also carried out using repeated 
measures analysis of variance with HAMD and PHQ15 as dependent variables. 
 
Página 5 de 9 
 
Results 
Seventy one patients (41 Amerindians and 30 Spaniards) were enrolled in this 
study. No statistically significant differences were found in gender composition between 
the two cohorts. Amerindians were younger (38.63 vs. 47.77; t = 3.674, p <. 0001) and 
less educated (11.90 vs. 15.33 years t = 3.932, p <. 0001). No significant differences 
were detected at baseline in HAMD, but Amerindians had higher scores in the 
somatization subscale of the PHQ (t = 4.067, p <.0001). Initial doses of Duloxetine 
were similar in both ethnic groups; with a mean of 36 mg. Significantly more Spaniards 
completed the protocol (80%) than did Amerindians (46.3%) (OR = 4.63, 95% CI = 
1.57-13.71, p<.005). Study withdrawal due to adverse effects occurred in 20% of 
Spaniard patients and 19.5% of Amerindian patients. Surprisingly enough, no Spaniard 
dropped out of the study by failing to attend scheduled appointments or withdrawing 
consent, whereas this occurred with Amerindians patients in 26.8% and 7.3% of cases 
respectively, half of them attended only the first visit. The flow diagram of the study 
can be seen as online extra material. 
After controlling for baseline sociodemographic variables, HAMD, PHQ-15 and 
duloxetine dose and using a multivariate logistic regression analysis, ethnic group was 
the only variable found to be statistically significant accounting for study retention. 
Twenty two patients (6 Spaniards (20%) and 16 Amerindians (39%) (OR = 2.560, 95% 
CI = .858-7.635, p=.087) reported at least one adverse effect, of which fourteen 
discontinued treatment (6, 20% Spaniards and 8, 19.5% Amerindians OR = 1.301, 95% 
CI = .316-3.362, p=.959). At the end of the study, no statistically significant differences 
in depression level were found between completers of both groups. Although both 
showed a reduction in somatization, Amerindians still had higher but not statistically 
significant levels than did Spaniards. No statistically significant differences were found 
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in remission or response. Spaniards received higher maximum dosage means than 
Amerindians (Spaniards 68.28±23.91 vs. Amerindians 56±20.44, Z=2.117, p=.034). All 
of the Spaniards correctly complied with the scheduled prescription, whereas three 
Amerindians did not correctly adhere to the treatment, and thus discontinued 
participation in the study. No statistically significant differences were found in 
remission (Spaniards 55.2% vs. Amerindians 37.5%, OR=2.051 95% CI=.737-5.709, 
p=.167) nor in response (Spaniards 62.1% vs. Amerindians 56.3%, OR=2.051 95% 
CI=.457-3.547, p=.644). Figure 1 shows the evolution of HAMD and PHQ-15 among 
groups both with an ITT and PP approach. As can be seen, the reduction of depression 
symptoms followed an identical pattern. In the ITT calculation, reduction of depressive 
symptoms was found to be statistically significant for the whole sample (Greenhouse-
Geisser F=97.508, p<.0001) but no difference between groups were significant 
(Greenhouse-Geisser F=.565, p=.536). Reduction of PHQ15 was also significant 
(Greenhouse-Geisser F=47.710, p<.0001). Amerindians showed a larger reduction in 
somatic symptoms as could be seen in the interaction of symptom reduction and group 
effect (Greenhouse-Geisser F=8.888, p<.001). 
Discussion 
The results of this study suggest that Duloxetine is effective in Amerindians and in 
Spaniards with properly adjusted doses.  More adverse effects were observed in 
Amerindians, although this was not significant, nor were they found to be related to 
differences in drop-outs. 
Statistically significant differences were found in remission when using LOCF. 
Differences in the dosage adjustment between groups may be due to Amerindian’s 
faster response and lower tolerability to high doses of Duloxetine. Study limitations 
include slow patient recruitment due to the volume of Amerindian patients seen at the 
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study site combined with the recency of the introduction of duloxetine into the Spanish 
market, and elevated rate of Amerindian drop-outs which, due to lack of reachability, 
prevented exploration of the relevant causes. In addition, the study used a narrowly 
defined ethnic category of “Amerindians”; even so, it must be recognized that a certain 
level of within group variability remains, even between those belonging to the same 
narrowly defined ethnic group. 
FIGURE 1. Evolution of HAMD and PHQ-15 among groups both with an ITT and PP 
approach. 
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